literature

HIV mutation literature information.

HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis.

PMID: 21311104 2011 Antiviral therapy

Abstract: RESULTS: Our studies revealed an increase in detection of 1.9-fold (95% confidence interval [CI] 1.3-2.7; P < 0.0005) for K103N, 4.4-fold (95% CI 1.2-16.6; P = 0.026) for Y181C, 4.8-fold (95% CI 1.5-15.1; P = 0.008) for L90M and 8.7-fold (95% CI 4.0-18.6; P < 0.0005) for M184V.

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

PMID: 21311109 2011 Antiviral therapy

Abstract: Two patients showed some evidence of PI resistance during transient HIV RNA elevations: one patient in the monotherapy arm had a single DRV mutation (L33F) when HIV RNA was 63 copies/ml (the virus was phenotypically sensitive to DRV [fold change 0.8]) and one PI pretreated patient taking tenofovir disoproxil fumarate/emtricitabine/DRV/r had re-emergence of pre-existing NRTI (M184V) and PI (V82I and L90M) mutations after a short treatment interruption (this virus remained phenotypically sensitive to DRV/r).

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

PMID: 21314993 2011 AIDS research and therapy

Conclusion: As shown in Table 3, failure of therapy in L76V-positive patients with ATV and/or SQV containing therapy was noticeable associated with an additional establishment of the protease gene mutation at position L90 M which resulted in resistance against all available PIs.

Conclusion: Six of eight patients who received a second genotypic resistance test following therapy failure were diagnosed positive for L90 M.

Conclusion: Thus, it might be questionable if SQV, which primarily selects L90 M should be replaced in favour of ATV.

Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

PMID: 21345162 2011 AIDS research and human retroviruses

Abstract: Of 41 children without virologic suppression with posttreatment HIV genotype data available, major resistance mutations were found in 32 (78%): 14 (36%) had PI mutations including V82A, M46I, and L90M; 29 (71%) had M184V/I; and three had NNRTI mutations (K103N, Y181C, and G190A).

New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.

PMID: 21417755 2011 AIDS research and human retroviruses

Abstract: Included were V32I (0.5%), M46I (2.0%), L90M (2.0%), T215C (0.5%), and Y188L (0.5%).

Abstract: Only one case carried resistance mutations to all three drug classes (L90M, L10I, and A71T to PI; T215C to NRTI; and Y188L to NNRTI).

The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.

PMID: 21446746 2011 Biochemistry

Result: However, in many, if not most, DRV resistant clinical isolates, a single resistance mutation does not occur alone but is associated with other mutations such as M46I and L90M, which are selected along with L76V in clinical settings.

Drug resistance mutations in patients infected with HIV-2 living in Spain.

PMID: 21558334 2011 The Journal of antimicrobial chemotherapy

Abstract: In PR the most frequent major changes were V47A (17%), I54M (17%), I82F (13%), L90M (29%) and L99F (29%).

Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected individuals (CoRIS).

PMID: 21663768 2011 Antiviral research

Abstract: The most prevalent resistance mutations were: T215 revertants (3.8%), D67NG (1.3%), K219QENR (1.2%) and M41L (1%), for NRTIs; K103N (3.2%), for NNRTIs; I54VLMSAT, M46I and L90M (0.7%), for PIs.

Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load.

PMID: 21701595 2011 PloS one

Discussion: Second, SDRMs that are slow to revert in the absence of selection (e.g., M41L, K103N, and T215X in RT and L90M in protease), implying a negligible cost to fitness, tend to have relatively high prevalence in therapy-naive sequences.

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

PMID: 22211659 2011 Current HIV research

Abstract: About 60% of tests reported L10FIRVC, M36ILV, M46IL, I54VLAMTS, V82AFTSLI, and L90M mutations in the protease region.

Browser Board

Co-occurred Entities

Filtrator